The IL-6 rs1800795 and rs1800796 polymorphisms are associated with coronary artery disease risk

Abstract

Studies examining the associations between the interleukin‐6 (IL‐6) rs1800795 and rs1800796 gene polymorphisms and risk of coronary artery disease (CAD) remain controversial. Our aim was to evaluate the accurately determine role of these two polymorphisms in CAD risk. PubMed, Embase, VIP, Wan fang and China National Knowledge Infrastructure databases were searched. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The trial sequential analysis (TSA) was conducted, and bioinformatics tools were employed. A total of thirty‐seven articles were obtained. For the IL‐6 rs1800795 polymorphism, 9411 CAD patients and 3161 controls were included, 4720 patients with CAD, and 5000 controls were included for the IL‐6 rs1800796 polymorphism. In the pooled analysis, significant associations were only observed for the rs1800796 polymorphism (allelic: OR [95%CI] = 1.28 [1.13, 1.44], dominant: OR [95%CI] = 1.35 [1.17, 1.57], recessive: OR [95%CI] = 1.35 [1.18, 1.55], heterozygote: OR [95%CI] = 1.26 [1.15, 1.37], homozygote: OR [95%CI] = 1.62 [1.23, 2.13]). Significant associations were detected in the Asian and Mongoloid populations and ‘more than 500’ subgroup for the rs1800795 polymorphism. TSA confirmed the true‐positive results for the rs1800796 polymorphism. The bioinformatics analysis showed that the two polymorphisms played important roles in the gene transcription. The IL‐6 rs1800796 polymorphism is associated with an increased susceptibility to CAD and is a risk factor for CAD. The IL‐6 rs1800795 polymorphism is associated with an increased risk of CAD in Asians, particularly in Chinese, and a decreased risk of CAD in an African population is remarkably observed.

Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis

“…There have been at least 12 published meta-analyses investigating the association of common IL6 SNPs with CAD, myocardial infarction (MI; or surrogates), and related clinical presentations. [5][6][7][9][10][11][12][13][14][15][16][17] However, flawed ethnic stratifications in these meta-analyses yielded inconsistent results [5][6][7][9][10][11][12][13][14][15][16][17]. Against this background, our objectives in this systematic review and metaanalysis were to: (i) ascertain the overall association of IL6 -174 G/C polymorphism with CAD, as well as separately amongst different ancestral populations, (ii) investigate the association of this polymorphic form with circulating IL-6 levels.…”

The pathogenic role of IL6 gene polymorhisms in type 1 diabetes mellitus

“…На данный момент роль цитокина в патогенезе СД1 не ясна, однако есть убедительные доказательства роли функциональных полиморфных маркёров в патогенезе других многофакторных заболеваний. Так, в одном крупном исследовании показана ассоциация двух полиморфных маркёров (rs1800795, rs1800796) с увеличением риска развития артериальной гипертензии [18]. В другом исследовании авторы свидетельствуют об ассоциации полиморфного маркёра rs1800795 гена IL6, на риск развития СД 2 типа [19].…”

Untitled

“…Two forms of low-density lipoprotein cholesterol (LDL-C) controlled by miR-126 especially cholesterol metabolism of LDL-C [12] and regulated highdensity lipoprotein (HDL) metabolism and reverse cholesterol transport with direct targeting of cellular cholesterol efflux [13,14]. IL-6 plays role in the development and maintenance of the inflammatory response in AS, pro-inflammatory, and immune-regulatory cytokine [15,16]. CAD-related miRNAs (miR126) are considered to be inflammatory-related miRNA influenced the inflammatory cytokines to coordinate the inflammatory processes [17].…”